Although cognitive dysfunctions in psychosis have classically been associated with schizophrenia, there is clinical evidence that some bipolar patients show cognitive disturbances either during acute phases or in remission periods. The authors critically review the data on cognitive impairment in bipolar disorder. The main computerized databases (Medline, Psychological Abstracts, Current Contents) have been consulted crossing the terms ‘cognitive deficits’, ‘neuropsychology’, ‘intellectual impairment’, ‘mania’, ‘depression’ and ‘bipolar disorder’. Changes in the fluency of thought and speech, learning and memory impairment, and disturbances in associational patterns and attentional processes are as fundamental to depression and mania as are changes in mood and behavior. Moreover, a significant number of bipolar patients show persistent cognitive deficits during remission from affective symptoms. However, there are several methodological pitfalls in most studies such as unclear remission criteria, diagnostic heterogeneity, small sample sizes, absence of longitudinal assessment, practice effect and poor control of the influence of pharmacological treatment. Most studies point at the presence of diffuse cognitive dysfunction during the acute phases of bipolar illness. Most of these deficits seem to remit during periods of euthymia, but some of them may persist in approximately one third of bipolar patients. Methodological limitations warrant further research in order to clear up the relationship between neuropsychological functioning and clinical, demographic and treatment variables in bipolar disorder.

Keywords:
Bipolar disorder, Cognitive disorders, Neuropsychology, Memory, Attention, Psychomotor performance, Speech, Executive function
1.
Kraepelin E: Manic depressive insanity and paranoia. Edinburgh, Livingstone, 1913.
2.
Winokur G, Clayton PJ, Reich T: Manic-Depressive Illness. St Louis, Mosby, 1969.
3.
Carlson GA, Kotin J, Davenport YB, Adland M: Follow-up of 53 bipolar manic-depressive patients. Br J Psychiatry 1974;124:134–139.
4.
Johnstone EC, Owens DGC, Frith CD, Calvert LM: Institutionalisation and the outcome of functional psychoses. Br J Psychiatry 1985;146:36–44.
5.
Gitlin MJ, Swendsen J, Heller TL, Hammen C: Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635–1640.
6.
Altshuler L: Bipolar disorder: Are repeated episodes associated with neuroanatomic and cognitive changes? Biol Psychiatry 1993;33:563–565.
7.
Williams JMG, Wats FN, Macleod C: Cognitive Psychology and Emotional Disorders. Chichester, Wiley, 1988.
8.
Abas MA, Sharakian BJ, Levy R: Neuropsychological deficits and CT scan changes in elderly depressives. Psychol Med 1990;20:507–520.
9.
Bulbena A, Berrios GE: Pseudodementia: Facts and figures. Br J Psychiatry 1986;148:87–94.
10.
Sapin LR, Berrettini WH, Nurnberger JI, Rothblat LA: Mediational factors underlying cognitive changes and laterality in affective illness. Biol Psychiatry 1987;22:979–986.
11.
Wolfe J, Granholm E, Butters N, Saunders E, Janowsky D: Verbal memory deficits associated with major affective disorders: A comparison of unipolar and bipolar patients. J Affect Disord 1987;13:83–92.
12.
Gruzelier J, Seymour K, Wilson L, Jolley A, Hirsch S: Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry 1988;45:623–629.
13.
Waddington JL, Brown K, O’Neill J, McLeon P, Kinsella A: Cognitive impairment, clinical course and treatment history in out-patients with bipolar affective disorder: Relationship to tardive dyskinesia. Psychol Med 1989;19:897–902.
14.
Dupont RM, Jernigan TL, Butters N, Delis D, Hesselink JR, Heindel W: Subcortical abnormalities detected in bipolar affective disorder using magnetic resonance imaging. Arch Gen Psychiatry 1990;47:55–59.
15.
Coffman JA, Bornstein RA, Olson SC, Schwarzkopf SB, Nasrallah HA: Cognitive impairment and cerebral structure by MRI in bipolar disorder. Biol Psychiatry 1990;27:1188–1196.
16.
Rund BR, Orbeck Al, Landro NI: Vigilance deficits in schizophrenics and affectively disturbed patients. Acta Psychiatr Scand 1992;86:207–212.
17.
Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Picker D, Kleinman JE: Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry 1993;150:1355–1362.
18.
Sax KW, Strakowski SM, McElroy SL, Keck PE, West SA: Attention and formal thought disorder in mixed and pure mania. Biol Psychiatry 1995;37:420–423.
19.
Dupont RM, Jernigan TL, Heindel W, Butters N, Shafer K, Wilson T, Hesselink J, Christian Gillin J: Magnetic resonance imaging and mood disorders. Localization of white matter and other subcortical abnormalities. Arch Gen Psychiatry 1995;52:747–755.
20.
Docherty N, Hawkins K, Rakfeldt J, Sledge WH: Working memory, attention and communication disturbances in schizophrenia. J Abnorm Psychol 1996;105:212–219.
21.
Albus M, Hubmann W, Wahlheim C, Sobizack N, Franz V, Mohr F: Contrasts in neuropsychological test profile between patients with first-episode schizophrenia and first-episode affective disorders. Acta Psychiatr Scand 1996;94:87–93.
22.
Kemp R, David A: Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 1996;169:444–450.
23.
Thomas P, Kearney G, Napier E, Ellis E, Leudar I, Johnston M: Speech and language in first onset psychosis: Differences between people with schizophrenia, mania and controls. Br J Psychiatry 1996;168:337–343.
24.
Paradiso S, Lamberty GJ, Garvey MJ, Robinson RG: Cognitive impairment in the euthymic phase of chronic unipolar depression. J Nerv Ment Dis 1997;185:748–754.
25.
Van Gorp WG, Altshuler L, Theberge DC, Wilkins J, Dixon W: Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. Arch Gen Psychiatry 1998;55:41–46.
26.
Kessing LV: Cognitive impairment in the euthymic phase of affective disorder. Psychol Med 1998;28:1027–1038.
27.
Golden CJ: Stroop Color and Word Test. Chicago, Stoelting, 1978.
28.
Partiot A, Pierson A, Renault B, Widlöcher D, Jouvent R: Traitement automatique de l’information, système frontal et émoussement affectif: de la clinique dimensionnelle aux processus cognitifs vers une psychobiologie des tempéraments. Encéphale 1994;20:511–519.
29.
Thomas J, Raoux N, Everett J, Dantchev N, Widlocher D: Le déficit de l’attention sélective et son évolution au cours de la dépression. Encéphale 1997;23:108–112.
30.
Trichard C, Martinot JL, Alagille M, Masure MC, Hardy P, Ginestet D, Féline A: Time course of prefrontal lobe dysfuncion in severely depressed in-patients: A longitudinal neuropsychological study. Psychol Med 1995;25:79–85.
31.
Rosvold HE, Mirsky AF, Sarason I, Bransome DE Jr, Beck LH: A continuous performance test of brain damage. J Consult Psychol 1956;20:343–350.
32.
Moffoot APR, O’Carroll RE, Bennie J, Carroll S, Dick H, Ebmeier KP, Goodwin GM: Diurnal variation of mood and neuropsychological function in major depression with melancholia. J Affect Disord 1994;32:257–269.
33.
Cornblatt BA, Lenzenweger MR, Erlenmeyer-Kimling L: The Continuous Performance Test, Identical Pairs Version. II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res 1989;29:65–85.
34.
Sereno AB, Holzman PS: Spatial selective attention in schizophrenic, affective disorder and normal subjects. Schizophr Res 1996;20:33–50.
35.
Strauss ME, Bohannon WE, Stephens JH, Pauker NE: Perceptual span in schizophrenia and affective disorders. J Nerv Ment Dis 1984;172:431–435.
36.
Sax KW, Strakowski SM, Zimmerman ME, DelBello MP, Keck PE Jr, Hawkins JM: Frontosubcortical neuroanatomy and the continuous performance test in mania. Am J Psychiatry 1999;156:139–141.
37.
Blackburn I: Mental and psychomotor speed in depression and mania. Br J Psychiatry 1975;132:329–335.
38.
Dunner D, Dwyer T, Fieve R: Depressive symptoms in patients with unipolar and bipolar affective disorder. Compr Psychiatry 1976;17:447–451.
39.
Cornell D, Suárez R, Berent S: Psychomotor retardation in melancholic and nonmelancholic depression: Cognitive and motor components. J Abnorm Psychol 1984;93:150–157.
40.
Hickie I: Validity of the Core. II. Neuropsychological tests; in Parker G, Hadzi-Pavlovic D (eds): Melancholia: A Disorder of Movement and Mood. Cambridge, Cambridge University Press, 1996.
41.
Alexopoulos GS, Meyers BS, Young RC Mattis S, Kakuma T: The course of geriatric depressions with ‘reversible dementia’: A controlled study. Am J Psychiatry 1993;150:1693–1699.
42.
Sackeim HA, Steif B: Neuropsychology of depression and mania; in Georgotas A, Cancro S (eds): Depression and Mania. Elsevier, Amsterdam, 1988.
43.
Reitan RM: Validity of the Trailmaking Test as an indication of organic brain damage. Percept Motor Skills 1958;8:271–276.
44.
Walker E, Green M: Motor proficiency and attentional-task performance by psychotic patients. J Abnorm Psychol 1982;91:261–268.
45.
Thomas J, Raoux N, Everett J, Dantchev N, Widlocher D: Le déficit de l’attention sélective et son évolution au cours de la dépression. Encéphale 1997;23:108–112.
46.
Schwartz F, Carr A, Munich R, Glauber S, Lesser B, Murray J: Reaction time impairment in schizophrenia and affective illness: The role of attention. Biol Psychiatry 1989;25:540–548.
47.
Wolff E, Putnam F, Post R: Motor activity, an affective illness: The relationship of amplitude and temporal distribution to changes in affective state. Arch Gen Psychiatry 1985;42:57–64.
48.
Porterfield T, Cook M, Deary IJ, Ebmeier KP: Neuropsychological function and diurnal variation in depression. J Clin Exp Neuropsychol 1997;19:906–913.
49.
Kupfer D, Weiss B, Foster F, Detre T, Delgado J, McPartland F: Psychomotor activity in affective states. Arch Gen Psychiatry 1974;30:765–768.
50.
Greden JF, Carroll BJ: Psychomotor function in affective disorders: An overview of new monitoring techniques. Am J Psychiatry 1981;138:1441–1448.
51.
Goodwin FK, Jamison KR: Manic-Depressive Illness. New York, Oxford University Press, 1990.
52.
Hoffman RE, Stopek S, Andreasen NC: A comparative study of manic versus schizophrenic speech disorganization. Arch Gen Psychiatry 1986;43:831–838.
53.
Souza VBN, Muir WJ, Walker MT, Glabus MF, Roxborough HM, Sharp CW, Dunan JR, Blackwood HR: Auditory P300 event-related potentials and neuropsychological performance in schizophrenia and bipolar affective disorder. Biol Psychiatry 1995;37:300–310.
54.
Fossati P, Deweer B, Raoux N, Allilaire JF: Les troubles de la récupération mnésique: un argument en faveur d’un dysfonctionnement des structures sous-cortico-frontales dans la dépression. Encéphale 1995;21:295–305.
55.
Luria AR: The Higher Cortical Functions in Man. New York, Basic, 1966.
56.
Heaton RK: Wisconsin Card Sorting Test Manual. Odessa, Psychological Assessment Resources, 1981.
57.
Morice R: Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Br J Psychiatry 1990;157:50–54.
58.
Benton AL, Hamser KS: Multilingual Aphasia Examination. Iowa City, AJA Associates, 1976.
59.
Moreaud O, Peguet I, Naegele B, Vincent T, Chabannes JP, Pellat J: Absence de dysfonctionnement frontal et de trouble de la mémoire de travail chez des jeunes schizophrènes. Encéphale 1998;24:52–56.
60.
Park S: Association of an oculomotor delayed response task and the Wisconsin Card Sort Test in schizophrenic patients. Int J Psychophysiol 1997;27:147–151.
61.
Berman KF, Doran AR, Pickar D, Weinberger DR: Is the mechanism of prefrontal hypofunction in depression the same as in schizophrenia? Regional cerebral blood flow during cognitive activation. Br J Psychiatry 1993;162:183–192.
62.
George MS, Ketter TA, Parekh PI, Gill DS, Huggins T, Morangell L, Pazzaglia PJ, Post RM: Spatial ability in affective illness: Differences in regional brain activation during a spatial matching task (H215O PET). Neuropsychiatry Neuropsychol Behav Neurol 1994;7:142–153.
63.
Savard RJ, Rey AC, Post RM: Halstead-Reitan Category Test in bipolar and unipolar affective disorders. J Nerv Ment Dis 1980;168:293–303.
64.
Squire LR: Declarative and nondeclarative memory: Multiple brain systems supporting learning and memory. J Cogn Neurosci 1992;4:232–243.
65.
Squire LR, Zola-Morgan S: Memory: Brain systems and behavior. Trends Neurosci 1988;11:170–175.
66.
Zola-Morgan S, Squire LR: The neuroanatomy of amnesia. Annu Rev Neurosci 1993;16:547–563.
67.
Norman KA, Schacter DL: Implicit memory, explicit memory, and false recollection: A cognitive neuroscience perspective; in Reder LM (ed): Implicit Memory and Metacognition. Hillsdale, Erlbaum, 1996.
68.
Delis DC, Kramer JH, Kaplan E, Ober BA: California Verbal Learning Test. New York, Psychological Corporation, 1987.
69.
Calev A, Erwin P: Recall and recognition in depressives: Use of matched tasks. Br J Clin Psychol 1985;24:127–128.
70.
Marcos T, Salamero M, Gutiérrez F, Catalán R, Gastó C, Lázaro L: Cognitive dysfunctions in recovered melancholic patients. J Affect Disord 1994;32:133–137.
71.
Sternberg DE, Jarvik ME: Memory functions in depression. Arch Gen Psychiatry 1976;33:219–224.
72.
Steif B, Sackeim H, Portoy S, Decina P, Malitz S: Effects of depression and ECT on anterograde memory. Biol Psychiatry 1986;21:921–930.
73.
Wechsler D: Wechsler Memory Scale-Revised. New York, Psychological Corp/Harcourt Brace Jovanovich, 1987.
74.
Whitehead A: Verbal learning and memory in elderly depressives. Br J Psychiatry 1973;123:203–208.
75.
Gass C, Russell E: Differential impact of brain damage and depression on memory test performance. J Consult Clin Psychol 1986;54:261–263.
76.
Breslow R, Kocsis J, Belkin B: Memory deficits in depression: Evidence utilizing the Wechsler Memory Scale. Percept Motor Skills 1980;51:541–542.
77.
Stromgen L: The influence of depression on memory. Acta Psychiatr Scand 1977;56:109–128.
78.
Harvey PD, Earle-Boyer EA, Wielgus MS, Levinson JC: Encoding, memory and thought disorder in schizophrenia and mania. Schizophr Bull 1986;12:252–261.
79.
Harvey PD, Earle-Boyer EA, Wielgus MS, Levinson JC: Cognitive deficits and thought disorder: A retest study. Schizophr Bull 1988;14:57–66.
80.
Andreasen NC, Hoffman RE, Grove WM: Language abnormalities in schizophrenia; in Menuck MN, Seeman MV (eds): New Perspectives in Schizophrenia. New York, Macmillan, 1985, pp 97–120.
81.
Speed M, Toner B, Shugar G, Gasbarro I: Thought disorder and verbal recall in acutely psychotic patients. J Clin Psychol 1991;47:735–744.
82.
Henry G, Weingartner H, Murphy D: Idiosyncratic patterns of learning and word association during mania. Am J Psychiatry 1971;128:564–573.
83.
Andreasen NJ, Powers PS: Overinclusive thinking in mania and schizophrenia. Br J Psychiatry 1974;125:452–456.
84.
Mitrushina M, Abara J, Blumenfeld A: A comparison of cognitive profiles in schizophrenia and other psychiatric disorders. J Clin Psychol 1996;52:177–190.
85.
Wechsler D: Wechsler Adult Intelligence Scale revised. Cleveland, Psychological Corporation, 1981.
86.
Kwapil TR, Hegley DC, Chapman LJ, Chapman JP: Facilitation of word recognition by semantic priming in schizophrenia. J Abnorm Psychol 1990;99:215–221.
87.
David AS: Negative priming (cognitive inhibition) in psychiatric patients: Effect of neuroleptics. J Nerv Ment Dis 1995;183:337–339.
88.
Danion JM, Villar Schroeder D, Zimmermann MA, Grang D, Sclienger JL, Singer L: Explicit memory and repetition priming in depression: Preliminary findings. Arch Gen Psychiatry 1991;48:707–711.
89.
Hertel P, Hardin TS: Remembering with and without awareness in a depressed mood: Evidence of deficits in initiative. J Exp Psychol Gen 1990;119:45–49.
90.
Danion JM, Kauffmann F, Grange D, Zimmerman MA: Affective valence of words, explicit and implicit memory in clinical depression. J Affect Disord 1995;34:227–234.
91.
Elliott CL, Greene RL: Clinical depression and implicit memory. J Abnorm Psychol 1992;101:572–574.
92.
Wittman P: The Babcock deterioration test in state hospital practice. J Abnorm Soc Psychol 1933;28:70–83.
93.
Rapaport D: Diagnostic Psychological Testing: The Theory, Statistical Evaluation and Diagnostic Application of a Battery of Tests. Chicago, Yearbook, 1946, vol 1.
94.
Shapiro MB, Nelson EH: An investigation of the nature of cognitive impairment in co-operative psychiatric patients. Br J Med Psychol 1955;28:239–256.
95.
Abrams R, Redfield J, Taylor MA: Cognitive dysfunction in schizophrenia, affective disorder and organic brain disease.Br J Psychiatry 1981;139:190–194.
96.
Donnelly E, Murphy D, Goodwin F, Waldman I: Intellectual function in primary affective disorder. Br J Psychiatry 1982;140:633–636.
97.
Clark DC, Clayton PS, Andreasen NC, Lewis C, Fawcet J, Scheftner WA: Intellectual functioning and abstraction ability in major affective disorders. Compr Psychiatry 1985;26:313–325.
98.
Shipley JE, Kupfer DJ, Spiker DG, Shaw DH, Coble PA, Neil JF, Cofsky J: Neuropsychological assessment and EEG sleep in affective disorders. Biol Psychiatry 1981;16:907–918.
99.
Taylor MA, Redfield J, Abrams R: Neuropsychological dysfunction in schizophrenia and affective disease. Biol Psychiatry 1981;16:467–478.
100.
McKay AP, Tarbuck AF, Shapleske J, McKenna PJ: Neuropsychological function in manic-depressive psychosis. Br J Psychiatry 1995;167:51–57.
101.
Johnson MH, Magaro P: Effects of mood and severity on memory processes in depression and mania. Psychol Bull 1987;101:28–40.
102.
Sweeney JA, Keilp JG, Hans G: Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 1991;37:297–308.
103.
Andreasen NC, Olsen S: Negative vs positive schizophrenia: Definition and validation. Arch Gen Psychiatry 1982;39:789–794.
104.
Minas IH, Stuart GW, Klimidis S, Jackson HJ, Singh BS, Copolov DL: Positive and negative symptoms in the psychoses: Multidimensional scaling of SAPS and SANS items. Schizophr Res 1992;8:143–156.
105.
Cuesta MJ, Peralta V: Cognitive disorders in the positive, negative in the disorganization schizophrenic syndromes. Psychiatry Res 1994;58:227–235.
106.
Maziade M, Roy MA, Martinez M, Cliche D, Fournier JP, Garneau Y, Nicole L, Montgrain N, Dion C, Ponton AM, Potvin A, Lavallée JC, Pirès A, Bouchard S, Boutin P, Brisebois F, Mérette C: Negative, psychoticism, and disorganized dimensions in patients with familial schizophrenia or bipolar disorder: Continuity and discontinuity between the major psychoses. Am J Psychiatry 1995; 152:1458–1463.
107.
Toomey R, Faraon SV, Simpson JC, Tsuang MJ: Negative, positive and disorganized symptom dimensions in schizophrenia, major depression and bipolar disorder. J Nerv Ment Dis 1998;186:470–476.
108.
Brébion G, Smith MJ, Amador X, Malaspina D, Gorman J: Clinical correlates of memory in schizophrenia: Differential links between depression, positive and negative symptoms and two types of memory impairment. Am J Psychiatry 1997;154:1538–1615.
109.
Fava GA: The concept of recovery in bipolar disorders. Psychother Psychosom 1996;65:2–13.
110.
Fava GA: Conceptual obstacles to research progress in affective disorders. Psychother Psychosom 1997;66:283–285.
111.
Fava GA: Subclinical symptoms in mood disorders: Pathophysiological and therapeutic implications. Psychol Med 1999;29:47–61.
112.
Judd LL, Hubbard B, Janowsky DS, Huey LY, Takahashi KI: The effect of lithium carbonate on the cognitive functions of normal subjects. Arch Gen Psychiatry 1977;34:355–357.
113.
Ananth J, Ghadirian AM, Engelsmann F: Lithium and memory: A review. Can J Psychiatry 1987;32:312–316.
114.
Shaw ED, Stokes PE, Mann JJ, Manevitz A: Effects of lithium carbonate on the memory and motor speed of bipolar outpatients. J Abnorm Psychol 1987;96:64–69.
115.
American Psychiatric Association, Work Group on Bipolar Disorder: Practice Guideline for the Treatment of Patients with Bipolar Disorder. Am J Psychiatry 1994;151(suppl):12.
116.
Gastó C, Vieta E, Blanch J, Pintor L: Psicofármacos en el Hospital General; in Rojo E, Cirera E (eds): Interconsulta Psiquiátrica. Barcelona, Biblio stm-Masson, 1997, pp 109–135.
117.
Thomson PJ, Trimble MR: Anticonvulsant drugs and cognitive functions. Epilepsia 1982;23:531–544.
118.
Spohn HE, Strauss ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989;98:367–380.
119.
Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990;16:477–499.
120.
Siever LJ, Keefe R, Bernstein DP, Coccaro EF, Klar HM, Zemishlany Z, Peterson AE, Davidson M, Mahon T, Horvath T, Mohs R: Eye tracking impairment in clinically identified patients with schizotypal personality disorders. Am J Psychiatry 1990;147:740–745.
121.
King DJ, Henry G: The effect of neuroleptics on cognitive and psychomotor function: A preliminary study in healthy volunteers. Br J Psychiatry 1992;160:647–653.
122.
Goldberg TE, Greenberg RD, Giffin SJ, Gold Jm, Kleinman JE, Picker D, Schulz SC, Weinberger DR: The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43–48.
123.
Green MF: Schizophrenia from a Neurocognitive Perspective: Probing the Impenetrable Darkness. Boston, Allyn and Bacon, 1998.
124.
Silver H, Gerisy N: Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients. Br J Psychiatry 1995;166:241–243.
125.
Holm RP, Moller-Madsen S, Videbech P, Hertel C, Povlsen UJ, Hemmingsen R: Neuropsychological deficit in newly diagnosed patients with schizophrenia or schizophreniform disorder. Acta Psychiatr Scand 1995;92:35–43.
126.
Gold JM, Goldberg TE, Kleinman JE, Weinberger DR: The impact of symptomatic state and pharmacological treatment on cognitive functioning of patients with schizophrenic and mood disorders; in Mohr E, Brouwers T (eds): Handbook of Clinical Trials. Amsterdam, Swets, 1991, pp 185–214.
127.
Deptula D, Pomara N: Effects of antidepressants on human performance: A review. J Clin Psychopharmacol 1990;10:105–111.
128.
Hartman DE: Neuropsychological Toxicology: Identification and Assessment of Human Neurotoxic Syndromes, ed 2. New York, Plenum Press, 1995.
129.
Pope HG, Jacobs A, Mialet JP, Yurgelun TD, Gruber S: Evidence for a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosom 1997;66:179–184.
130.
Rieder RO, Mann LS, Weinberger DR, Kammen DP, Post R: Computed tomographic scans in patients with schizophrenia, schizoaffective and bipolar affective disorder. Arch Gen Psychiatry 1983;40:735–739.
131.
Dolan RJ, Bench CJ, Liddle PF, Friston KJ, Frith CD, Grasby PM, Frackowiak RS: Dorsolateral prefrontal cortex dysfunction in the major psychoses: Symptom or disease specificity? J Neurol Neurosurg Psychiatry 1993:56:1290–1294.
132.
Andreasen NC, Swayze V, Flaum M, Alliger R, Cohen G: Ventricular abnormalities in affective disorder: Clinical and demographic correlates. Am J Psychiatry 1990;147:893–900.
133.
Dewan MJ, Haldipur CV, Boucher MF, Ramachandran T, Major LF: Bipolar affective disorder. II. EEG, neuropsychological, and clinical correlates of CT abnormality. Acta Psychiatr Scand 1988;77:677–682.
134.
Altshuler LL, Conrad A, Hauser P, Li X, Guze B, Denikoff K, Tourtellotte W, Post RM: Reduction of temporal lobe volume in bipolar disorder: A preliminary report of magnetic resonance imaging. Arch Gen Psychiatry 1991;48:482–483.
135.
Harvey I, Persaud R, Ron MA, Baker G, Murray RM: Volumetric MRI measurements in bipolars compared with schizophrenics and healthy controls. Psychol Med 1994;24:689–699.
136.
Elkis H, Friedman L, Wise A, Meltzer HY: Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders: Comparison with controls or patients with schizophrenia. Arch Gen Psychiatry 1995;52:735–746.
137.
Zipursky RB, Lambe EK, Kapur S, Mikulis D: Cerebral gray matter volume deficits in first episode psychosis. Arch Gen Psychiatry 1998;55:540–546.
138.
Faith-Berman K, Doran A, Pickar D, Weinberger D: Is the mechanism of prefrontal dysfunction in depression the same as in schizophrenia? Br J Psychiatry 1993;162:183–192.
139.
Parellada E, Lomeña F: Neuroimagen; in Vieta E, Gastó C (eds): Trastornos Bipolares. Barcelona, Springer, 1997, pp 222–239.
140.
Damasio AR: Towards a neuropathology of emotion and mood. Nature 1997;386:769–770.
141.
Martinot JL, Hardy P, Feline A, Huret JD, Mazoyer B, Attar-Levy D, Pappata S, Syrota A: Left prefrontal glucose hypometabolism in the depressed state: A confirmation. Am J Psychiatry 1990;47:1313–1317.
142.
Bench CJ, Francowiak RSJ, Dolan RJ: Changes in regional cerebral blood flow on recovery from depression. Psychol Med 1995;25:247–261.
143.
Bench CJ, Friston KJ, Brown RG, Scott LC, Frackowiak RSJ, Dolan RJ: The anatomia of melancholia: Focal abnormalities of cerebral blood flow in major depression. Psychol Med 1992; 22:607–615.
144.
Andreasen NC, Rezai K, Alliger R, Swayze V, Flaum M, Kirchner P, Cohen G, O’Leary DS: Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: Assessment with xenon-133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992;49:943–958.
145.
Goodwin GM, Cavanagh JTO, Glabus MF, Kehoe RF, O’Carroll RE, Ebmeier KP: Uptake of 99mTc-exametazime shown by single photon emission computed tomography before and after lithium withdrawal in bipolar patients: Association with mania. Br J Psychiatry 1997;170:426–430.
146.
Blackwood DHR, Sharp CW, Walker MT, Doody GA, Glabus MF, Muir WJ: Implications of comorbidity for genetic studies of bipolar disorder: P300 and eye tracking as biological markers for illness. Br J Psychiatry 1996;168:85–92.
147.
Muir WJ, St Clair DM, Blackwood DHR: Long-latency auditory event-related potential in schizophrenia and in bipolar and unipolar affective disorder. Psychol Med 1991;21:867–879.
148.
Prohaska ML, Stern RA, Nevels CT, Mason GA: The relationship between thyroid status and neuropsychological performance in psychiatric outpatients maintained on lithium. Neuropsych Neuropsychol Behav Neurol 1996;9:30–34.
149.
Vieta E, Gastó C, Martínez de Osaba MJ, Nieto E, Canto TJ, Otero A, Vallejo J: Prediction of depressive relapse in remitted bipolar patients using corticotropin-releasing hormone challenge test. Acta Psychiatr Scand 1997;95:205–211.
150.
Vieta E, Martínez de Osaba MJ, Colom F, Martínez-Arán A, Benabarre A, Gastó C: Enhanced corticotropin response to corticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients. Psychol Med, in press.
151.
Laroche I, Hodgins S, Toupin J: Liens entre les symptômes et le fonctionnenment social chez des personnes souffrant de schizophrénie ou de trouble affectif majeur. Can J Psychiatry 1995;40:27–34.
152.
Colom F, Vieta E, Martínez A, Jorquera A, Gastó C: What is the role of psychotherapy in the treatment of bipolar disorder? Psychother Psychosom 1998;67:3–9.
153.
Basco MR, Rush AJ: Cognitive-Behavioral Therapy for Bipolar Disorder. New York, Guilford Press, 1996.
154.
Bauer M, McBride L: Structured group psychotherapy for bipolar disorder: The life goals program. New York, Springer, 1996.
155.
Frank E, Kupfer DJ, Ehlers CL, Monk TH, Cornes C, Carter S, Frankel D: Interpersonal and social rhythm therapy for bipolar disorder: Integrating interpersonal and behavioral approaches. Behav Ther 1994;17:153–156.
156.
Antonuccio DO, Danton WG, De Nelsky GY, Greenberg RP, Gordon JS: Raising questions about antidepressants. Psychother Psychosom 1999;68:3–14.
157.
Miklowitz DJ, Goldstein MJ, Nuechterlein KH, Snyder KS, Mintz J: Family factors and the course of bipolar affective disorder. Arch Gen Psychiatry 1988;45:225–231.
© 2000 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.